Analysis of the chronic lymphocytic leukemia coding genome: role of <i>NOTCH1</i> mutational activation

Giulia Fabbri(Cancer Genetics (United States)), Silvia Rasi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Владимир Трифонов(Cancer Genetics (United States)), Hossein Khiabanian(Cancer Genetics (United States)), Jing Ma(St. Jude Children's Research Hospital), Adina Grunn(Cancer Genetics (United States)), Marco Fangazio(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Daniela Capello(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Sara Monti(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Stefania Cresta(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Ernesto Gargiulo(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Francesco Forconi(University of Siena), Anna Guarini(Sapienza University of Rome), Luca Arcaini(University of Pavia), Marco Paulli(University of Pavia), Luca Laurenti(Università Cattolica del Sacro Cuore), Luigi Maria Larocca(Università Cattolica del Sacro Cuore), Roberto Marasca(University of Modena and Reggio Emilia), Valter Gattei(Centro di Riferimento Oncologico), David Oscier(Royal Bournemouth Hospital), Francesco Bertoni(Institute of Oncology Research), Charles G. Mullighan(St. Jude Children's Research Hospital), Robin Foà(Sapienza University of Rome), Laura Pasqualucci(Cancer Genetics (United States)), Raúl Rabadán(Cancer Genetics (United States)), Riccardo Dalla‐Favera(Cancer Genetics (United States)), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
The Journal of Experimental Medicine
June 13, 2011
Cited by 604Open Access
Full Text

Abstract

The pathogenesis of chronic lymphocytic leukemia (CLL), the most common leukemia in adults, is still largely unknown. The full spectrum of genetic lesions that are present in the CLL genome, and therefore the number and identity of dysregulated cellular pathways, have not been identified. By combining next-generation sequencing and copy number analysis, we show here that the typical CLL coding genome contains <20 clonally represented gene alterations/case, including predominantly nonsilent mutations, and fewer copy number aberrations. These analyses led to the discovery of several genes not previously known to be altered in CLL. Although most of these genes were affected at low frequency in an expanded CLL screening cohort, mutational activation of NOTCH1, observed in 8.3% of CLL at diagnosis, was detected at significantly higher frequency during disease progression toward Richter transformation (31.0%), as well as in chemorefractory CLL (20.8%). Consistent with the association of NOTCH1 mutations with clinically aggressive forms of the disease, NOTCH1 activation at CLL diagnosis emerged as an independent predictor of poor survival. These results provide initial data on the complexity of the CLL coding genome and identify a dysregulated pathway of diagnostic and therapeutic relevance.


Related Papers

No related papers found

Powered by citation graph analysis